Aura Biosciences, Inc. · NASDAQ:AURA
Aura Biosciences — Technical Presentation (September 2022)
20 slides from Aura Biosciences's technical presentation, September 2022
Slide 1: New Developments in Belzupacap Sarotalocan (AU-011) in Ocular Oncology
New Developments in Belzupacap Sarotalocan (AU-011), an Investigational Virus-Like Drug Conjugate (VDC) in Ocular Oncology Research sponsored by Health Holland in collaboration with Aura Biosciences Martine Jager, MD, PhD Cx Virus-Like Particle Cytotoxic dye Virus-Like Drug (VLP) Conjugate (VDC)
Slide 2: Overview
Overview o Belzupacap sarotalocan (AU-011) mechanism of action o Collaborative work: synergistic action of belzupacap sarotalocan in combination with immune checkpoint inhibitors o Preclinical evidence in choroidal metastasis 2
Slide 3: Targeted Oncology Platform - Virus-Like Drug Conjugates (VDCs)
Targeted Oncology Platform - Virus-Like Drug Conjugates (VDCs) Virus-Like particles are conjugated to a Cytotoxic VDCs can recognize tumor-associated heparan-sulfate proteoglycans drug to form the Virus-Like Drug Conjugate Cx Virus-Like Particle (VLP) Cytotoxic Drug Virus-Like Drug Conjugate (VDC) T
Slide 4: Belzupacap Sarotalocan is a VDC with a Novel Dual Mechanism of Action
Belzupacap Sarotalocan (AU-011) is a Virus-Like Drug Conjugate with a Novel Dual Mechanism of Action Light Activated Drug Belzupacap sarotalocan Belzupacap sarotalocan is a novel VDC that consists of the Virus-Like Particle conjugated to ~200 molecules of phthalocyanine dye Potential Key Differentia
Slide 5: AU-011 has shown binding and uptake in uveal melanoma cells
AU-011 has shown binding and uptake in uveal melanoma cells Cancer cells AU-011 AU-011 5 1-sep-22
Slide 6: Clinical Outcomes Support Safety and Efficacy in Choroidal Melanoma
Clinical Outcomes Support Safety and Efficacy of Belzupacap Sarotalocan as a Potential Treatment for Choroidal Melanoma Fundus photo and ultrasound at baseline Fundus photo and ultrasound at 1 year Tumor thickness: 1.87mm; LBD: 9.04mm Tumor Thickness: 1.80mm; LBD: 8.75mm All imaging performed as per
Slide 7: Potential Applicability in Other Ocular Cancers - Choroidal Metastasis
Belzupacap Sarotalocan Potential Applicability in Other Ocular Cancers is Being Investigated - Choroidal Metastasis Common Features of C-Mets 3 C-Mets Originates from Multiple Primary Cancers1 Unilateral (72%) Unilateral (72%) Skin Solitary (72%) Breast 40-53% 2% Choroidal location (88%) Kidne
Slide 8: AU-011 has shown binding and uptake in multiple types of tumor cells
AU-011 has shown binding and uptake in multiple types of tumor cells Cancer cells AU-011 AU-011 8 1-sep-22
Slide 9: Dose-dependent Activity For Cancer Types Known To Metastasize To The Choroid
Belzupacap Sarotalocan Has Demonstrated Dose-dependent Activity For Cancer Types Known To Metastasize To The Choroid BREAST EMT6 RENAL RENCA COLON CT26 Syngeneic Mouse Model, EMT-6 Syngeneic Mouse Model, RENCA Syngeneic Mouse Model, CT-26 Single administration of belzupacap sarotalocan inhibited tum
Slide 10: Conclusions – Belzupacap Sarotalocan
Conclusions – Belzupacap Sarotalocan Choroidal Melanoma Choroidal Metastasis Demonstrated safety and early efficacy in Showed dose-dependent activity in vivo a Phase 1b/2 study supports further using syngeneic mouse models for cancer clinical development in a pivotal study in types known to metastas
Slide 11: AU-011 is a virus like drug conjugate with a novel mechanism of action
AU-011 is an investigational virus like drug conjugate with a novel mechanism of action 1. Cancer cell directed cytotoxicity 2. Induction of antitumor immune responses 11 1-sep-22
Slide 12: Damage-associated molecular patterns (DAMPs)
Damage-associated molecular patterns (DAMPs) Showalter A. et al. Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine. 2017;97:123-132 12 1-sep-22
Slide 13: Release of DAMPs following AU-011 treatment
Release of DAMPs following AU-011 treatment Showalter A. et al. Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine. 2017;97:123-132 13 1-sep-22
Slide 14: Rationale for combining AU-011 and Immune Checkpoint Inhibition
Rationale for combining AU-011 treatment and Immune Checkpoint Inhibition: T cells are inhibited through ICI’s Beyrend et al. (2019): PD-L1 blockade induces LAG-3 expression → Co-targeting of PD-L1 & LAG-3 Wykes M. N. & Lewin S. R. Immune checkpoint blockade in infectious diseases. Nature Reviews Im
Slide 15: AU-011 + Light activation combined with ICI enhanced response (1 of 2)
AU-011 + Light activation combined with ICI enhanced treatment response compared to either treatment alone (1 of 2) 15 1-sep-22
Slide 16: AU-011 + Light activation combined with ICI enhanced response (2 of 2)
AU-011 + Light activation combined with ICI enhanced treatment response compared to either treatment alone (2 of 2) 16 1-sep-22
Slide 17: Treatment of primary and distant tumors enhanced with ICI (1 of 3)
Treatment of primary and distant tumors was enhanced by AU-011 + Light activation with ICI versus either treatment alone (1 of 3) 17 1-sep-22
Slide 18: Treatment of primary and distant tumors enhanced with ICI (3 of 3)
Treatment of primary and distant tumors was enhanced by AU-011 + Light activation with ICI versus either treatment alone (3 of 3) 18 1-sep-22
Slide 19: Conclusions – Collaborative Work
Conclusions – Collaborative Work AU-011 + Light activation: • Induced cancer cell-directed cytotoxicity • Released DAMPs and induced maturation of antigen-presenting cells • Combined with ICI using anti-PD-L1 & anti-LAG-3 antibodies showed potential to induce complete and lasting tumor responses in
Slide 20: Conclusions – Belzupacap Sarotalocan
Conclusions – Belzupacap Sarotalocan Treatment Of Primary Tumor And Choroidal Melanoma Choroidal Metastasis Distant Lesions In Combination With ICIs* Demonstrated safety and Showed dose-dependent activity Belzupacap sarotalocan plus ICIs efficacy supports starting a in vivo using syngeneic mouse (an
Aura Biosciences — Technical Presentation (September 2022) on 6ix